PMID- 27007153
OWN - NLM
STAT- MEDLINE
DCOM- 20171212
LR  - 20210129
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 16
DP  - 2016 Apr 19
TI  - A novel prognostic score model incorporating CDGSH iron sulfur domain2 (CISD2) 
      predicts risk of disease progression in laryngeal squamous cell carcinoma.
PG  - 22720-32
LID - 10.18632/oncotarget.8150 [doi]
AB  - BACKGROUND: The role of CDGSH iron sulfur domain 2 (CISD2) in laryngeal squamous 
      cell carcinoma (LSCC) remains unclear. RESULTS: CISD2 were up-regulated in LSCC 
      tissues compared with adjacent noncancerous tissues both at mRNA and protein 
      levels. CISD2 was significantly correlated with T stage, lymph node metastasis, 
      clinical stage and disease progression. A prognostic model (C-N model) for PFS 
      was subsequently constructed based on independent prognostic factors including 
      CISD2 and N classification. This model significantly divided LSCC patients into 
      three risk subgroups and was more accurate than the prediction efficacy of TNM 
      classification in the training cohort (C-index, 0.710 vs 0.602, P = 0.027) and 
      validation cohort (C-index, 0.719 vs 0.578, P = 0.014). METHODS: Real-time PCR 
      and Western blotting were employed to examine the expression of CISD2 in eight 
      fresh paired LSCC samples. Immunohistochemistry was performed to assess CISD2 
      expression in 490 paraffin-embedded archived LSCC samples. A prognostic model for 
      progression-free survival (PFS) was built using independent factors. The 
      concordance index (C-Index) was used to evaluate the prognostic ability of the 
      model. CONCLUSIONS: CISD2 was up-regulated in LSCC. The novel C-N model, which 
      includes CISD2 levels and N classification, is more accurate than conventional 
      TNM classification for predicting PFS in LSCC.
FAU - Yang, Lin
AU  - Yang L
AD  - Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 
      510060, China.
AD  - State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
FAU - Hong, Shaodong
AU  - Hong S
AD  - Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 
      510060, China.
AD  - State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
FAU - Wang, Yan
AU  - Wang Y
AD  - Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 
      510060, China.
AD  - State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
FAU - He, Zhenyu
AU  - He Z
AD  - Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 
      510060, China.
AD  - State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
FAU - Liang, Shaobo
AU  - Liang S
AD  - The First Hospital of Foshan, Foshan 528000, China.
FAU - Chen, Haiyang
AU  - Chen H
AD  - The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510060, China.
FAU - He, Shasha
AU  - He S
AD  - Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 
      510060, China.
AD  - State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
FAU - Wu, Shu
AU  - Wu S
AD  - Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 
      510060, China.
AD  - State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
FAU - Song, Libing
AU  - Song L
AD  - Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 
      510060, China.
AD  - State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
FAU - Chen, Yong
AU  - Chen Y
AD  - Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 
      510060, China.
AD  - State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CISD2 protein, human)
RN  - 0 (Membrane Proteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*analysis
MH  - Carcinoma, Squamous Cell/mortality/*pathology
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Female
MH  - Head and Neck Neoplasms/mortality/*pathology
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Laryngeal Neoplasms/mortality/*pathology
MH  - Male
MH  - Membrane Proteins/*biosynthesis
MH  - Middle Aged
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - Up-Regulation
PMC - PMC5008395
OTO - NOTNLM
OT  - CDGSH iron sulfur domain2 (CISD2)
OT  - biomarker
OT  - laryngeal squamous cell carcinoma (LSCC)
OT  - progression free survival (PFS)
COIS- All the authors declare that they have no conflicts of interest.
EDAT- 2016/03/24 06:00
MHDA- 2017/12/13 06:00
PMCR- 2016/04/19
CRDT- 2016/03/24 06:00
PHST- 2015/10/09 00:00 [received]
PHST- 2016/02/23 00:00 [accepted]
PHST- 2016/03/24 06:00 [entrez]
PHST- 2016/03/24 06:00 [pubmed]
PHST- 2017/12/13 06:00 [medline]
PHST- 2016/04/19 00:00 [pmc-release]
AID - 8150 [pii]
AID - 10.18632/oncotarget.8150 [doi]
PST - ppublish
SO  - Oncotarget. 2016 Apr 19;7(16):22720-32. doi: 10.18632/oncotarget.8150.